Kari Leigh Keese Sells 2,961 Shares of Axonics, Inc. (NASDAQ:AXNX) Stock

Axonics, Inc. (NASDAQ:AXNX) CFO Kari Leigh Keese sold 2,961 shares of Axonics stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $69.41, for a total transaction of $205,523.01. Following the transaction, the chief financial officer now directly owns 40,362 shares of the company’s stock, valued at approximately $2,801,526.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Axonics Trading Up 0.2 %

Axonics stock traded up $0.15 during midday trading on Thursday, reaching $69.63. The stock had a trading volume of 347,075 shares, compared to its average volume of 731,744. The company has a fifty day moving average price of $68.90 and a two-hundred day moving average price of $68.04. Axonics, Inc. has a 12 month low of $48.30 and a 12 month high of $69.91. The company has a market capitalization of $3.55 billion, a P/E ratio of -217.00 and a beta of 0.81.

Axonics (NASDAQ:AXNX) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.10 by $0.03. Axonics had a negative return on equity of 0.27% and a negative net margin of 0.42%. The firm had revenue of $114.57 million during the quarter, compared to the consensus estimate of $112.83 million. During the same quarter in the previous year, the company posted ($0.15) earnings per share. The company’s quarterly revenue was up 23.3% on a year-over-year basis. On average, equities research analysts predict that Axonics, Inc. will post 0.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Edgestream Partners L.P. purchased a new position in shares of Axonics during the first quarter valued at approximately $605,000. Janus Henderson Group PLC grew its stake in shares of Axonics by 637.7% in the 1st quarter. Janus Henderson Group PLC now owns 178,322 shares of the company’s stock worth $12,298,000 after acquiring an additional 154,149 shares in the last quarter. Gabelli Funds LLC purchased a new stake in shares of Axonics in the first quarter valued at about $12,271,000. Hsbc Holdings PLC lifted its position in shares of Axonics by 26.5% during the fourth quarter. Hsbc Holdings PLC now owns 65,494 shares of the company’s stock valued at $4,076,000 after purchasing an additional 13,734 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. purchased a new position in Axonics during the first quarter worth about $16,573,000. Institutional investors and hedge funds own 99.48% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reissued a “hold” rating on shares of Axonics in a research report on Monday, August 5th. Eight research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Axonics currently has a consensus rating of “Hold” and an average target price of $69.57.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.